Biotech Companies Report Quarterly Financial Results - Analyst Notes on Intrexon, Acorda, Anika, Sangamo and Spectrum

NEW YORK, May 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Intrexon Corporation (NYSE: XON), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Anika Therapeutics, Inc. (NASDAQ: ANIK), Sangamo Biosciences, Inc. (NASDAQ: SGMO) and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2531-100free.

--
Intrexon Corporation Analyst Notes
On May 7, 2014, Intrexon Corporation (Intrexon) reported Q1 2014 financial results. The Company's total revenues increased 102.2% YoY to $7.9 million. The Company noted that the increase was due to the recognition of deferred revenue for upfront payments received from 13 collaborations or expansions signed by Intrexon from April 1, 2013 to March 31, 2014; recognition of research and development services performed by the Company pursuant to the new collaborations; and increased research and development services performed by Intrexon for collaborations in effect before march 31, 2013. Net income stood at $4.1 million, or $0.04 per diluted share, compared to a net loss of $42.7 million, or $7.54 per diluted share, in Q1 2013. The full analyst notes on Intrexon are available to download free of charge at:

http://www.analystsreview.com/2531-XON-14May2014.pdf

--
Acorda Therapeutics, Inc. Analyst Notes
On May 6, 2014, Acorda Therapeutics, Inc. (Acorda) reported Q1 2014 financial results. Revenues totaled $80.5 million, up 12.0% YoY. Net income was at $0.7 million, or $0.02 per diluted share, compared to a net loss of $1.1 million, or $ 0.03 per diluted share, in Q1 2013. Ron Cohen, M.D., President and CEO of Acorda said, "During the quarter, a fifth AMPYRA patent was issued and listed in the Orange Book. AMPYRA's commercial success is supporting the development of an exciting pipeline of novel therapies." He added, "We were pleased to resume enrollment of our second clinical trial of GGF2 in chronic heart failure and to have completed the dose escalation phase of our Phase 1 rHIgM22 trial for remyelination in MS, with no serious or limiting adverse events." For full-year 2014, the Company is reiterating its expectation of AMPYRA net revenue to be between $328.0 million to $335.0 million. The full analyst notes on Acorda are available to download free of charge at:

http://www.analystsreview.com/2531-ACOR-14May2014.pdf

--
Anika Therapeutics, Inc. Analyst Notes
On April 29, 2014, Anika Therapeutics, Inc. (Anika) reported Q1 2014 financial results. The Company's revenue totaled $34.0 million, up 123.1% YoY. Net income was $15.0 million, or $0.97 per diluted share, compared to $3.1 million, or $0.21 per diluted share, in Q1 2013. "Our total revenue more than doubled from the first quarter last year, materially driven by milestone and contract revenue associated with our U.S. license agreement for Monovisc®. This revenue growth together with the impact of our ongoing productivity improvements in operations resulted in a significant year-over-year increase in Anika's earnings for the quarter," said Charles H. Sherwood, Ph.D., President and CEO of Anika. "Looking ahead, we remain positive and excited about our outlook for 2014. Anika is on track to meet its business goals. These include U.S. commercial launch of Monovisc®, clinical success and European regulatory advancement of Cingal™, as well as clinical progress on HyalofastTM and our longer-term pipeline opportunities." The full analyst notes on Anika are available to download free of charge at:

http://www.analystsreview.com/2531-ANIK-14May2014.pdf

--
Sangamo Biosciences, Inc. Analyst Notes
On May 6, 2014, Sangamo Biosciences, Inc. (Sangamo) reported Q1 2014 financial results. In Q1 2014, the Company reported revenues of $8.1 million, up 75.6% YoY. The Company highlighted that Q1 2014 revenues were generated from its collaboration agreement with Shire International GmbH (Shire), Biogen Idec (Biogen) and Sigma-Aldrich Corporation (Sigma), enabling technology agreements and research grants. Consolidated net loss was $7.6 million, or $0.12 per diluted share, compared to $6.9 million, or $0.13 per diluted share, in Q1 2013. For full-year 2014, Sangamo expects revenues in the range of $45.0 million to $50.0 million. The full analyst notes on Sangamo are available to download free of charge at:

http://www.analystsreview.com/2531-SGMO-14May2014.pdf

--
Spectrum Pharmaceuticals, Inc. Analyst Notes
On May 8, 2014, Spectrum Pharmaceuticals, Inc. (Spectrum) reported Q1 2014 financial results. During the quarter, the Company's revenues totaled $40.1 million, up 3.8% YoY. Q1 2014 net loss was $27.6 million, or $0.44 per diluted share, compared to a net loss of $5.4 million, or $0.09 per diluted share in Q1 2013. Rajesh C. Shrotriya, MD, Chairman and CEO of Spectrum Pharmaceuticals said, "With three significant pipeline milestones in the next few months, this is a very exciting time in Spectrum's history. The FDA approval decision for Beleodaq is expected by August 9. Following the recent positive data from CE Melphalan, we expect to file for approval for this improved formulation of Melphalan. The Phase 2 trial for SPI-2012 is enrolling well. If the SPI-2012 development program is successful, we will compete in the multi-billion dollar neutropenia market. We are looking forward to these exciting milestones in the near term." The full analyst notes on Spectrum are available to download free of charge at:

http://www.analystsreview.com/2531-SPPI-14May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review